(S)-Thalidomide

CAS No. 841-67-8

(S)-Thalidomide( —— )

Catalog No. M33094 CAS No. 841-67-8

(S)-Thalidomide ((S)-(-)-Thalidomide) is the S-isomer of Thalidomide with immunomodulatory, anti-inflammatory, anticancer, anti-angiogenic, and pro-apoptotic activities, used in studying leprosy erythema nodosum and myeloma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 53 In Stock
10MG 85 In Stock
25MG 181 In Stock
50MG 288 In Stock
100MG 506 In Stock
500MG 1071 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (S)-Thalidomide
  • Note
    Research use only, not for human use.
  • Brief Description
    (S)-Thalidomide ((S)-(-)-Thalidomide) is the S-isomer of Thalidomide with immunomodulatory, anti-inflammatory, anticancer, anti-angiogenic, and pro-apoptotic activities, used in studying leprosy erythema nodosum and myeloma.
  • Description
    (S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN) .
  • In Vitro
    (S)-Thalidomide treatment results in a reduction in cell viability in U266 cells with an IC50 of 362 μM.(S)-Thalidomide treatment increased apoptosis in a dose-dependent manner in U266 cells.There are changes in the expression profile of genes involved in angiogenesis and apoptosis, but the changes are most dramatic in the apoptotic genes. In particular, the expression of I-κB kinase is decreased by two-fold, which is associated with a four-fold decrease in NF-κB expression. (S)-Thalidomide increases the Bax:Bcl-2 ratio, alsoincreases I-kB protein levels, and decreases NF-kB activity. A dramatic decrease in Bcl-2 expression with (S)-Thalidomide suggests a possible enhancement of cytotoxic effect if combined with other cytotoxic agents.Cell Viability Assay Cell Line:U266 MM cells Concentration:0 μM, 10 μM, 100 μM, 150 μM, 200 μM, 1000 μM Incubation Time:3 days Result:A reduction in cell viability was observed in U266 cells.Apoptosis Analysis Cell Line:U266 MM cells Concentration:100 μM, 150 μM, 200 μM, 1000 μM Incubation Time:3 days Result:Increased apoptosis in U266 cells.
  • In Vivo
    Thalidomide does cause limb reduction defects in chick embryos as long as the embryos are directly exposed to the drug. The most useful techniques are implanting Thalidomide-soaked beads into the embryo immediately adjacent to the limb territory or soaking presumptive chick limb territories in Thalidomide and then grafting the explants to a host embryo celom. Thalidomide affects the chick limb grafted to a host embryo in a dose response fashion. Furthermore, (S)-Thalidomide is more teratogenic than (R)-Thalidomide.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    841-67-8
  • Formula Weight
    258.23
  • Molecular Formula
    C13H10N2O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 83.33 mg/mL (322.70 mM; Ultrasonic )
  • SMILES
    O=C1N(C(=O)C=2C1=CC=CC2)[C@@H]3C(=O)NC(=O)CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Liu WM, et al. s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J. 2004;5(3):247-54.?
molnova catalog
related products
  • NecroX-7

    NecroX-7 is a small molecule necrosis modulator and potent antioxidant molecule.

  • Polygalacin D

    Polygalacin D shows anti- proliferation, anti-inflammary, and hepatoprotective activities.

  • DMU-212

    DMU-212, a methylated form of Resveratrol, shows antimitotic, antiproliferative, and antioxidant activities. DMU-212 induces mitotic arrest through the activation of ERK1/2 protein and the promotion of apoptosis.